Business Daily Media

Men's Weekly

.

New investors Thiel and Novogratz introduced to Bionomics by Apeiron Investment Group as part of successful second placement capital raising

  • Written by PR Newswire

SYDNEY, Sept. 3, 2020 /PRNewswire/ -- Following overwhelming shareholder approval, the scheduled second placement of 54,333,000 new shares by Bionomics is proceeding and expected to complete shortly. In accordance with the Subscription Agreement between Apeiron and Bionomics, Apeiron has introduced Michael Novogratz, Peter Thiel, and Jason Camm, Managing Director of Lifesciences at Thiel Capital, to Bionomics. Each of these investors, along with Aperion, will subscribe for ordinary shares in Bionomics as part of the scheduled second placement.  

Apeiron's backing has ensured that the Company has the funds needed to make significant progress in its Phase II clinical trials of BNC210 for PTSD. BNC210 recently received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of PTSD. 

In addition to BNC210, Bionomics is collaborating with Merck US on several compounds for the treatment of cognitive deficits in Alzheimer's and Schizophrenia. The Company also has promising oncology assets undergoing Phase II clinical trials funded by Bristol Myers-Squibb and other pharma partners.

Apeiron ContactAaron WeaverHead of Capital Markets, Apeiron Investment Group+44 (0) 7850009833   aw@apeiron-investments.com[1] 

About Apeiron Investment Group Apeiron Investment Group Ltd, Malta, is the family office and merchant banking business of Christian Angermayer. Apeiron focuses on Financial Services (especially fintech and crypto assets), Deep-Tech (AI, space-tech, cybersecurity etc.), Life Sciences, Media & Entertainment and Real Estate & Prop-Tech.

About Bionomics Limited Bionomics is a biopharmaceutical company dedicated to making better treatments for cancer, central nervous system disorders such as anxiety, depression and Alzheimer's Disease. Based in Adelaide, Australia, with operations in San Diego, USA and a wholly owned subsidiary in Strasbourg, France, Bionomics is listed on the Australian Securities Exchange (ASX) under the code BNO, and the US OTCQX market under the code BNOE.

References

  1. ^ aw@apeiron-investments.com (www.prnasia.com)

Read more https://www.prnasia.com/story/archive/3114736_EN14736_0

Demand for Home Batteries surges as Federal Rebate Kicks In

A leading provider of energy solutions VoltX Energy has seen a 400% increase in demand for home batteries in the past three weeks as people put d...

Why Sport Remains the Safest Bet in an Uncertain World

When Rome was in crisis, its leaders did not retreat to the Senate. They went to the circus. To the chariot races. To the gladiators. Sport was no...

THE FINE LINE WITHIN HILARIOUS SIGNAGE DESIGN FAILS

It seems like design failures still occur in today’s modern branding era, despite rigorous rounds of approvals behind the scenes. One signage show...

Deputy Announces Exclusive Global Partnership with Predelo to Bring AI to Shift-Based Businesses

Deputy, the global people platform for shift-based businesses, has announced an exclusive partnership with Predelo, an AI Decision Agent-as-a-Serv...

Leftover Budget? The Last-Minute EOFY Tip to Drive Business Success in FY25/26

The countdown is on. With just days left until EOFY, now’s the time to make your remaining 2024–2025 budget work harder and smarter. After workin...

pay.com.au appoints new CEO and Managing Director

The former COO will lead the company’s next growth phase, with ex-CEO Edward Alder transitioning into the role of Managing Director AUSTRALIA, 25...

Sell by LayBy